Simon Tian

5.4k total citations
32 papers, 1.0k citations indexed

About

Simon Tian is a scholar working on Pulmonary and Respiratory Medicine, Emergency Medical Services and Plant Science. According to data from OpenAlex, Simon Tian has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 7 papers in Emergency Medical Services and 4 papers in Plant Science. Recurrent topics in Simon Tian's work include Cystic Fibrosis Research Advances (26 papers), Pediatric health and respiratory diseases (7 papers) and Neonatal Respiratory Health Research (7 papers). Simon Tian is often cited by papers focused on Cystic Fibrosis Research Advances (26 papers), Pediatric health and respiratory diseases (7 papers) and Neonatal Respiratory Health Research (7 papers). Simon Tian collaborates with scholars based in United States, United Kingdom and Canada. Simon Tian's co-authors include Gregory S. Sawicki, Michael W. Konstan, Mark Higgins, David Waltz, Gautham Marigowda, Nataliya Volkova, Diana Bilton, C Simard, Alexander Elbert and Bruce C. Marshall and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Simon Tian

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Tian United States	13	989	98	96	89	69	32	1.0k
Stefanie J. Millar United States	14	821 0.8×	47 0.5×	65 0.7×	48 0.5×	96 1.4×	30	910
Daniela Savi Italy	10	366 0.4×	29 0.3×	11 0.1×	13 0.1×	70 1.0×	34	427
Ioanna Loukou Greece	13	284 0.3×	30 0.3×	22 0.2×	8 0.1×	119 1.7×	44	420
Seth Walker United States	6	366 0.4×	19 0.2×	13 0.1×	34 0.4×	28 0.4×	13	398
Marina Litvin United States	10	213 0.2×	62 0.6×	13 0.1×	7 0.1×	18 0.3×	12	353
Adèle Coriati Canada	14	459 0.5×	67 0.7×	4 0.0×	12 0.1×	58 0.8×	39	677
Jonathan McCormick United Kingdom	11	552 0.6×	26 0.3×	12 0.1×	4 0.0×	20 0.3×	13	628
Marcia Katz United States	5	446 0.5×	58 0.6×	6 0.1×	8 0.1×	13 0.2×	8	564
S. Bertasi Italy	9	236 0.2×	39 0.4×	18 0.2×	4 0.0×	12 0.2×	17	315
Sonia Volpi Italy	13	374 0.4×	41 0.4×	12 0.1×	3 0.0×	31 0.4×	36	500

Countries citing papers authored by Simon Tian

Since Specialization

Citations

This map shows the geographic impact of Simon Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Tian more than expected).

Fields of papers citing papers by Simon Tian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Tian. The network helps show where Simon Tian may publish in the future.

Co-authorship network of co-authors of Simon Tian

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Tian. A scholar is included among the top collaborators of Simon Tian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Tian. Simon Tian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertoch, Todd, Daneshvari R. Solanki, Matthew W. Swisher, et al.. (2025). Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 142(6). 1085–1099. 11 indexed citations

Egbuna, Ogo, et al.. (2024). Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults. SHILAP Revista de lepidopterología. 4(1). 64–73. 3 indexed citations

Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society. 20(8). 1144–1155. 13 indexed citations

Ramsey, Bonnie W., Christoph U. Correll, David R. DeMaso, et al.. (2023). Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. American Journal of Respiratory and Critical Care Medicine. 209(3). 299–306. 26 indexed citations

Rayment, Jonathan H., Fadi Asfour, Margaret Rosenfeld, et al.. (2022). A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine. 206(10). 1239–1247. 20 indexed citations

Bachman, Eric, et al.. (2022). Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 47(6). 817–825. 13 indexed citations

Chilvers, Mark, Jane C. Davies, Carlos Milla, et al.. (2021). Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. The Lancet Respiratory Medicine. 9(7). 721–732. 27 indexed citations

Wilson, John, Xiaojun You, Don S. Urquhart, et al.. (2020). VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. Journal of Cystic Fibrosis. 20(3). 499–505. 19 indexed citations

Davies, Jane C., Claire Wainwright, Gregory S. Sawicki, et al.. (2020). Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 203(5). 585–593. 67 indexed citations

10.

Hoppe, Jordana E., Mark Chilvers, Félix Ratjen, et al.. (2020). WS19.2 Long-term safety of lumacaftor/ivacaftor therapy in persons with cystic fibrosis aged 2–5 years homozygous for the F508del-CFTR mutation (F/F). Journal of Cystic Fibrosis. 19. S31–S31. 1 indexed citations

11.

Pilewski, Joseph M., K. De Boeck, Jerry A. Nick, et al.. (2020). Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulmonary Therapy. 6(2). 303–313. 6 indexed citations

12.

McNamara, John, Susanna A. McColley, Gautham Marigowda, et al.. (2019). Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine. 7(4). 325–335. 102 indexed citations

13.

Volkova, Nataliya, Kristin A. Moy, Jennifer Evans, et al.. (2019). Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Journal of Cystic Fibrosis. 19(1). 68–79. 186 indexed citations

14.

Rosenfeld, Margaret, Steve Cunningham, William T. Harris, et al.. (2019). An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB). Journal of Cystic Fibrosis. 18(6). 838–843. 90 indexed citations

15.

McNamara, John, Susanna A. McColley, C.A. Owen, et al.. (2018). WS01.5 A 2-part, phase 3 single-arm study to evaluate the safety and pharmacokinetics (PK) of lumacaftor/ivacaftor (LUM/IVA) combination therapy in patients (pts) aged 2 to 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation. Journal of Cystic Fibrosis. 17. S2–S3. 1 indexed citations

16.

Bessonova, Leona, Nataliya Volkova, Mark Higgins, et al.. (2018). Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 73(8). 731–740. 143 indexed citations

17.

Davies, Jane C., Claudio Colombo, Elizabeth Tullis, et al.. (2018). WS01.6 Preliminary safety and efficacy of triple combination CFTR modulator regimens in cystic fibrosis. Journal of Cystic Fibrosis. 17. S3–S3. 8 indexed citations

18.

Ratjen, Félix, Simon Tian, Gautham Marigowda, et al.. (2017). WS13.4 Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6–11 years (yrs) with cystic fibrosis (CF) homozygous for F508del-CFTR: a randomized placebo (PBO)-controlled phase 3 trial. Journal of Cystic Fibrosis. 16. S24–S24. 10 indexed citations

19.

Taylor‐Cousar, Jennifer L., Manu Jain, Tarik Haddad, et al.. (2017). Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. Journal of Cystic Fibrosis. 17(2). 228–235. 56 indexed citations

20.

Konstan, Michael W., Edward F. McKone, Richard B. Moss, et al.. (2016). Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. The Lancet Respiratory Medicine. 5(2). 107–118. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact